HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that MicroVal has approved the iQ-Check STEC VirX Kit for the real-time PCR detection of virulence genes in Shiga toxin-producing Escherichia coli (STEC) in raw meat products (375 g — excluding poultry) and raw dairy products (25 g).
MicroVal is an international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages. The technical protocol and result interpretation for this study were carried out according to the ISO-16140-2:2016 and MicroVal technical rules.
The validation study demonstrated excellent results with excellent sensitivity with the iQ-Check STEC VirX method compared to the reference method ISO/TS 13136. The kit was evaluated on parameters such as sensitivity, relative level of detection, inclusivity and exclusivity. In addition, Bio-Rad’s iQ-Check Free DNA Removal Solution was validated as part of the workflow to remove free/dead cell DNA from the samples before PCR testing.
The iQ-Check STEC VirX Kit is recognized by renowned international validation organizations, such as AOAC INTERNATIONAL, and is the screening step for the United States Department of Agriculture Microbiology Laboratory Guidebook (USDA MLG) reference method Chapter 5C.02.
Shiga toxin-producing Escherichia coli (STEC) can be highly pathogenic to humans, potentially leading to hemorrhagic colitis, hemolytic uremic syndrome (HUS) and death. The iQ-Check STEC VirX Kit is a complete, flexible, and open solution, enabling industrial microbiology laboratories to control and adjust their quality assurance procedures more effectively. The certificate (2021LR96) is available on the MicroVal website.
For more information on Bio-Rad’s complete range of iQ-Check Real-Time PCR Test Kits, please visit http://www.bio-rad.com/iqcheck
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 7,900 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
510-741-5653
wendy_lauer@bio-rad.com